Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study

Gastroenterology. 2020 Sep;159(3):1129-1131.e3. doi: 10.1053/j.gastro.2020.05.053. Epub 2020 May 22.

Famotidine Research Group:
Magdalena E Sobieszczyk, David D Markowitz, Aakriti Gupta, Max R O'Donnell, Jianhua Li, David A Tuveson, Zhezhen Jin, William C Turner, Donald W Landry

¹ Division of Digestive and Liver Diseases, Columbia University Irving Medical Center-New York Presbyterian Hospital, New York, New York. Electronic address: def2004@cumc.columbia.edu.
² Division of General Internal Medicine, Department of Medicine, Northwell Health, Manhasset, New York; Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.
³ Division of Digestive and Liver Diseases, Columbia University Irving Medical Center-New York Presbyterian Hospital, New York, New York.
⁴ Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York.
⁵ Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts; Office of the Assistant Secretary for Public Health Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC.
⁶ Division of Digestive and Liver Diseases, Columbia University Irving Medical Center-New York Presbyterian Hospital, New York, New York. Electronic address: ja660@cumc.columbia.edu.

No abstract available

Keywords: Coronavirus 2019; Famotidine; Histamine-2 Receptor Antagonists; SARS-CoV-2.

MeSH terms